CHS 131

Drug Profile

CHS 131

Alternative Names: AMG 131; INT 131; INT131 besylate; T 0903131; T 131

Latest Information Update: 22 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tularik
  • Developer Coherus BioSciences; InteKrin Therapeutics
  • Class Anti-inflammatories; Antihypercalcaemics; Antihyperglycaemics; Insulin sensitisers; Neuroprotectants; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists; Peroxisome proliferator-activated receptor gamma modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Type 2 diabetes mellitus

Most Recent Events

  • 28 Apr 2017 Efficacy data from a phase IIb trial in Multiple sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 13 Mar 2017 CHS 131 is available for licensing as of 13 Mar 2017. https://www.coherus.com/our-scientific-platform/
  • 31 Dec 2016 Coherus BioSciences completes a phase IIb trial in Multiple Sclerosis in Russia before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top